- November 08, 2018 Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview
- November 05, 2018 Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
- October 11, 2018 Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206
- September 27, 2018 Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results
- September 25, 2018 Spero Therapeutics Announces Presentations at IDWeek 2018
- September 19, 2018 Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October
- August 28, 2018 Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference
- August 14, 2018 Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors
- August 09, 2018 Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
- July 16, 2018 Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
Displaying 1 - 10 of 68 results